> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# New Indication Sought for AbbVie’s Rinvoq
- URL: https://www.fdaweb.com/new-indication-sought-for-abbvies-rinvoq/
- Published: 2020-08-25T12:00:00.000Z
- Updated: 2026-09-14T16:26:19.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5147509

AbbVie says it has submitted an application to FDA for a new indication for its Rinvoq (upadacitinib) 15 mg once daily to treat adult patients with active ankylosing spondylitis. A company [statement](https://www.marketwatch.com/press-release/abbvie-submits-regulatory-application-to-fda-for-rinvoqtm-upadacitinib-for-the-treatment-of-adults-with-active-ankylosing-spondylitis-2020-08-25?tesla=y&ref=fdaweb.com) says the application is supported by data from a Phase 2/3 study in which Rinvoq demonstrated significant improvements in signs and symptoms in patients with active ankylosing spondylitis.

Rinvoq is described as a selective and reversible JAK inhibitor that is being studied in several immune-mediated inflammatory diseases. It was approved by FDA 8/2019 for adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate.